Immune Receptor Articles & Analysis
12 news found
He received his B.A. in business economics from the University of California, Santa Barbara, and holds an active CPA license. Immune-Onc also announced successful completion of dose escalation in the first-in-human clinical trial (NCT05054348) of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 ...
Immune-Onc retains global development and commercial rights to IO-108. ...
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
Immune-Onc retains global development and commercial rights to IO-108 and IO-202. ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the first patient has been treated with IO-108, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), in a Phase 1 clinical ...
Multicenter Phase 1 study to evaluate IO-108 as both monotherapy and in combination with pembrolizumab in China Represents the first LILRB2-targeting antibody with IND clearance in China and the company’s fourth IND globally A Phase 1 trial evaluating IO-108 in patients with advanced solid tumors is currently enrolling in the U.S. Immune-Onc Therapeutics, Inc. ...
LAIR1 is an immune inhibitory receptor expressed on lymphocytes and myeloid cells that correlates with worse survival in several cancers. ...
Chengcheng (Alec) Zhang, Professor of Physiology at UT Southwestern Medical Center and Scientific Founder of Immune-Onc, will give an expert presentation on the LILRB/ILT family of receptors as myeloid checkpoint targets in immuno-oncology at 2:30 PM EDT. ...
ABOUT LILRB4 (also known as ILT3) LILRB4, also known as ILT3, is an immune inhibitory transmembrane receptor expressed by monocytic myeloid cells, including dendritic cells, monocytes, monocytic myeloid-derived suppressor cells and tumor-associated macrophages. ...
The symposium will focus on the emerging landscape of technologies leveraging gamma delta T cells for anticancer therapeutics and will be moderated by Andrea van Elsas, Ph.D., chair, scientific advisory board at LAVA, and will feature presentations from leading experts in the field of gamma delta T cell immunity. Prof. Hans van der Vliet, M.D., Ph.D., professor, medical ...
AMICA is a downloadable database of annotated multi-omic immune cells that includes information about gene expression, proteins, T-cell and B-cell receptors for immune cells, clinical and/or lab data, and a downloadable artificial intelligence software platform designed for characterizing and analyzing immune cells, as well as ...
ByImmunai
The S1 protein mediates the attachment of the virus to the host cell surface receptors whilst the S2 protein mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein and it has at least three conformational forms. The OVM recombinant overlapping peptide vaccine will target both S proteins to generate the immunity that ...